The PROPKD Score

Émilie Cornec-Le Gall(Université Européenne de Bretagne), Marie‐Pierre Audrézet(Inserm), Annick Rousseau(Inserm), Maryvonne Hourmant(Centre Hospitalier Universitaire de Nantes), E. Renaudineau(Hôpital Broussais), Christophe Charasse(Yves Rocher (France)), Marie-Pascale Morin(Université Rennes 2), Marie‐Christine Moal(Centre Hospitalier Régional Universitaire de Brest), Jacques Dantal(Centre Hospitalier Universitaire de Nantes), Bassem Wehbe(Hôpital Laennec), Régine Perrichot(Centre hospitalier Bretagne Atlantique), T. Frouget(Université Rennes 2), Cécile Vigneau(Université Rennes 2), J. Potier(Yves Rocher (France)), Philippe Jousset(École nationale des ponts et chaussées), Marie-Paule Guillodo(Santé Publique France), P. Siohan(Hôpital Laennec), Nazim Terki(Satimo (France)), T. Sawadogo(Centre Hospitalier de Bretagne Sud), Didier Legrand(Centre Hospitalier de Bretagne Sud), Victorio Menoyo-Calonge(North Carolina Exploring Cultural Heritage Online), Seddik Benarbia(Centre Hospitalier de Cornouaille), Dominique Besnier(Centre Hospitalier Saint-Nazaire), Hélène Longuet(Université de Tours), Claude Férec(Université Européenne de Bretagne), Yannick Le Meur(Université Européenne de Bretagne)
Journal of the American Society of Nephrology
July 6, 2015
Cited by 351Open Access
Full Text

Abstract

The course of autosomal dominant polycystic kidney disease (ADPKD) varies among individuals, with some reaching ESRD before 40 years of age and others never requiring RRT. In this study, we developed a prognostic model to predict renal outcomes in patients with ADPKD on the basis of genetic and clinical data. We conducted a cross-sectional study of 1341 patients from the Genkyst cohort and evaluated the influence of clinical and genetic factors on renal survival. Multivariate survival analysis identified four variables that were significantly associated with age at ESRD onset, and a scoring system from 0 to 9 was developed as follows: being male: 1 point; hypertension before 35 years of age: 2 points; first urologic event before 35 years of age: 2 points; PKD2 mutation: 0 points; nontruncating PKD1 mutation: 2 points; and truncating PKD1 mutation: 4 points. Three risk categories were subsequently defined as low risk (0-3 points), intermediate risk (4-6 points), and high risk (7-9 points) of progression to ESRD, with corresponding median ages for ESRD onset of 70.6, 56.9, and 49 years, respectively. Whereas a score ≤3 eliminates evolution to ESRD before 60 years of age with a negative predictive value of 81.4%, a score >6 forecasts ESRD onset before 60 years of age with a positive predictive value of 90.9%. This new prognostic score accurately predicts renal outcomes in patients with ADPKD and may enable the personalization of therapeutic management of ADPKD.


Related Papers

No related papers found

Powered by citation graph analysis